Introduction
Dopaminergic and glutamatergic terminals converge onto the same dendritic spines of dopamineceptive neurons in dopamine (DA) target regions, forming "synaptic triads" (Freund et al., 1984; Goldman-Rakic et al., 1989; Carr and Sesack, 1996) . This triadic heterosynaptic architecture provides a structural basis for a close interplay between DA and glutamate systems, which is essential for many cognitive and motivational processes (Berke and Hyman, 2000; Schultz, 2002) . A balanced DA-glutamate interaction is, to a large degree, mediated by the functional cross talk between D 1 , the predominant subtype of the D 1 -class receptors, and the NMDA glutamate receptor in postsynaptic neurons. These receptors colocalize extensively at synaptic, parasynaptic, and nonsynaptic sites in dendritic spines and shafts (Hara and Pickel, 2005; Pickel et al., 2006) . Classically, D 1 receptor activation enhances NMDA receptor activity through the cAMP/protein kinase A (PKA)/dopamine and cAMP-regulated phosphoprotein-32 (DARPP-32)/protein phosphatase 1 (PP1) pathways (Lachowicz and Sibley, 1997; Missale et al., 1998; Greengard et al., 1999) . D 1 activation also induces rapid trafficking of intracellular NMDA receptors to the postsynaptic membrane, thus enhancing NMDA receptor function, via a tyrosine kinase signaling mechanism (Dunah and Standaert, 2001) .
Recent studies reveal that NMDA receptors also reciprocally regulate D 1 activity via direct physical coupling. D 1 interacts with the NMDA receptor subunits 1 (NR1) through carboxyl tails of these receptors (Lee et al., 2002) . Association with NMDA receptors facilitates D 1 trafficking to the cell surface and inhibits D 1 internalization Fiorentini et al., 2003; Pei et al., 2004) . Ligand-occupied NMDA receptors also constrain the mobility of laterally diffusing dendritic D 1 receptors and recruit them to spines through a diffusion trap mechanism (Scott et al., 2006) . Assuming that activation of NMDA receptors recruits D 1 receptors to the plasma membrane, which in turn facilitates the activity and surface targeting of NMDA receptors, a positive feedback loop is created (Cepeda and Levine, 2006) . This loop, if not controlled, might result in concomitant overactivation of both D 1 and NMDA receptors, jeopardizing neuronal integrity and triggering neurotoxicity (Choi, 1988; Bozzi and Borrelli, 2006) .
The postsynaptic scaffold PSD-95 interacts with NMDA receptor NR2 subunits through its first two PSD-95/Dlg/ZO-1 homology (PDZ) domains (Kornau et al., 1995; Niethammer et al., 1996) , which may play a role in "functionally" localizing NMDA receptors in the synapse (Kennedy, 2000; Kim and Sheng, 2004) and in regulating synaptic efficacy (Migaud et al., 1998; Stein et al., 2003; Ehrlich and Malinow, 2004; Béïque et al., 2006; Xu et al., 2008) . PSD-95 also interacts with D 1 via the C terminus (CT) of the receptor and the N terminus (NT) of PSD-95, an interaction that regulates D 1 trafficking (Zhang et al., 2007) . Together with the demonstrated D 1 -NR1 association and overlapping subcellular distributions of these proteins (Valtschanoff et al., 1999; Aoki et al., 2001; Hara and Pickel, 2005) , a tertiary protein com-plex containing these proteins may exist in the brain, in which the interplay between D 1 and NMDA receptors is fine-tuned. Here, we provide evidence that PSD-95 associates with D 1 and the NMDA receptor complex and negatively regulates the physical and functional interactions between these receptors.
Materials and Methods
Mice. All experiments were conducted in accordance with the National Institutes of Health guidelines for the care and use of animals and with an approved animal protocol from the Harvard Medical Area Standing Committee on Animals. PSD-95 wild-type (WT) and knock-out (KO) mice (Yao et al., 2004) were housed under standard laboratory conditions (12 h light/dark cycle) with food and water provided ad libitum.
Plasmid constructs. Plasmids encoding HA-D 1 (hemagglutinin-tagged D 1 receptors), PSD-95-GFP (green fluorescent protein-tagged PSD-95), NR1, NR2B, and PSD-95-GFP mutants ⌬NT-GFP, ⌬1&2-GFP, ⌬NT, 1&2-GFP, and NT-GFP have been described previously (Tezuka et al., 1999; Zhang et al., 2007) . PSD-95 small-hairpin (sh)RNA targeting sequence (Elias et al., 2006) in pLLox3.7 vector was a kind gift from Dr. Roger A. Nicoll (University of California, San Francisco, San Francisco, CA). The control shRNA (TCACAGTCGGATCCATCACTCAGTATA) was inserted into pLLox3.7. All constructs were generated by PCR and verified by automated sequencing.
Cell culture and transfection. Human embryonic kidney (HEK) 293, HEK293T, and HEK293 cells stably expressing the rhesus monkey D 1 receptor (D 1 -stable cells) were cultured and transfected as previously described (Zhang et al., 2007) . Embryonic day 18 -19 (E18 -19) rat and mouse primary neurons were grown on poly-D-lysine-coated plates in neurobasal medium supplemented with B27 and 1% GlutaMax (Invitrogen). Hippocampal neurons were transfected with sh-PSD-95 or shcontrol and HA-D 1 by Lipofectamine 2000 (Invitrogen) or nucleofection (Amaxa).
Lentivirus production and neuronal infection. HEK293T cells (2 ϫ 10 6 ) were cotransfected with pLLox3.7 and helper vectors, pDelta8.9 and pVSV-G, using TransFectin (Bio-Rad). The supernatant was collected after 72 h and titer was determined by infection of HEK293T cells. Striatal neurons were infected by lentivirus particles expressing sh-PSD-95 or sh-control with a titer of MOI 2 at 11 days in vitro, and grown for 6 additional days before Western blot analyses and cAMP assays. The infection efficiency routinely reached Ͼ70%.
Immunocytochemistry, confocal microscopy, and immunofluorescence. Hippocampal neurons were fixed in 4% paraforaldehyde/4% sucrose at room temperature for 15 min, permeabilized, and blocked, as previously described (Zhang et al., 2007) . Cells were incubated with the following primary antibodies overnight at 4°C: anti-D 1 (1:50; Sigma), anti-PSD-95 (1:200), and anti-NR1 (1:50; BD PharMingen), followed by incubation with secondary antibodies conjugated with appropriate Alexa dyes (1: 500; Invitrogen) at room temperature for 1 h. Cells were mounted on glass slides. D 1 internalization was measured as described (Zhang et al., 2007) . Briefly, HA-D 1 -transfected HEK293 cells or hippocampal neurons were incubated with a HA antibody (1:100, Covance) at 4°C or 15°C, respectively. After wash, cells were stimulated with SKF 81297 ((Ϯ)-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1 H-3-benzazepine hydrobromide) (30 min, 37°C) in the presence or absence of NMDA receptor agonists and/or antagonists, as specified. Surface HA-D 1 receptors were labeled with an Alexa Fluor 647-conjugated secondary antibody. The internalized HA-D 1 receptor was recognized by an Alexa Fluor 568-conjugated secondary antibody after permeabilization. Confocal images were acquired using a Leica confocal microscope at the following excitation/emission wavelengths: 488/519 nm, 568/604 nm, or 647/669 nm. Image stacks were acquired under the same confocal settings along the z-axis, and were flattened into a single image using a maximum projection and analyzed with MetaMorph (Universal Imaging). Surface and internal D 1 fluorescence intensities were measured as integrated pixel intensities, and the internalization index for each cell was defined as the ratio of the internalized fluorescence intensity to the total fluorescence intensity. HA-D 1 internalization in neurons was performed at the soma.
For quantification of colocalization, dendritic segments of a neuron containing Ͼ50 fluorescence clusters were selected and traced. NR1 clusters were selected automatically in the pseudo-colored "blue" channel as discrete puncta of intensity Ͼ1.5-fold brighter than the background fluorescence. Selected clusters were transferred to the red channel to measure the D 1 fluorescence. Colocalization of D 1 over NR1 was measured as the percentage of integrated D 1 pixel intensities that overlapped with the NR1 fluorescence in individual clusters and averaged for each neuron. All groups to be compared were run simultaneously using cells from the same culture preparations and transfection condition.
Immunoprecipitation and Western blotting. HEK293(T) cells or cultured neurons were briefly sonicated in 25 mM Tris-HCl containing 150 mM NaCl, 3 mM KCl, 1 mM EDTA, and protease inhibitors, and the supernatants were extracted by centrifuge at 13,000 ϫ g for 30 min. Mouse forebrain structures (i.e., striata, hippocampi, and cortices) were dissected, homogenized, and extracted in a deoxycholate (DOC) buffer as previously described (Zhang et al., 2007) . Protein extracts were incubated with anti-D 1 (10 l; Sigma), anti-NR1 (4 g; Upstate Biotechnology), or anti-HA (5 l; Covance) antibodies at 4°C overnight with gentle rotation. Precipitated protein complexes were captured by Protein A/G agarose beads (Santa Cruz Biotechnology), immobilized to polyvinylidene difluoride (PDVF) membranes, incubated with anti-D 1 (1:200), anti-PSD-95 (1:500; BD Transduction Laboratories), anti-NR1 (1:200), anti-NR2B (1:200; Upstate Biotechnology), anti-GST (glutathione S-transferase) (1:1000; Santa Cruz Biotechnology), anti-actin (1:1000; Millipore), or anti-GFP (green fluorescent protein) (1:1000; Santa Cruz Biotechnology) antibodies as specified. Horseradish peroxidaseconjugated secondary antibodies and signals were detected by an ECLbased LAS-3000 image system (Fujifilm). Densitometric analysis was performed within linear range using ImageGauge (Fujifilm).
GST fusion proteins and pull-down assay. GST fusion proteins encoding D 1 receptor C-terminal fragments CT1 (aa 361-389), CT2 (aa 385-415), or CT3 (aa 414 -446) were generated by PCR and subcloned into pGEX6P-1 vector (GE Healthcare) in-frame. GST fusion protein production was induced by 0.5 mM isopropyl-␤-D-thiogalactopyranoside (Promega) for 2 h in BL21 bacterium and immobilized on glutathioneSepharose 4B agarose (GE Healthcare). Equal amounts of GST fusion proteins were incubated at 4°C overnight with lysates of HEK293 cells overexpressing PSD-95-GFP or cultured rat striatal neurons, followed by washes with ice-cold PBS containing 0.1% Triton X-100. The pulleddown proteins were resolved by SDS-PAGE and analyzed by Western blotting.
cAMP enzyme immunoassay. D 1 -stable HEK293 cells transiently transfected with NR1 and NR2B cDNAs in the presence or absence of PSD-95-GFP coexpression, or striatal neurons infected with lentiviral particles expressing sh-PSD-95 or sh-control, were stimulated by SKF 81297 for 30 min in the presence or absence of NMDA receptor agonist/antagonist combinations, as specified. Whole-cell cAMP accumulation was measured using the Direct cAMP Enzyme Immunoassay Kit (Sigma or GE Healthcare) following manufacturers' instructions. cAMP concentrations were measured as optical density at 405 or 450 nm by a microplate reader (PerkinElmer).
Radioligand competition binding. Cells were homogenized in 5 mM Tris-HCI containing 2 mM EDTA and protease inhibitors, and centrifuged at 3400 ϫ g for 30 min at 4°C. The pellet was resuspended in binding buffer [5 mM Tris containing (in mM): 8.5 HEPES, 120 NaCl, 5. (Zhang et al., 2007) , and NMDA receptors, which, in this study, represented coexpression of the NR1 and the NR2B subunits. Immunoblot analysis of whole-cell lysates showed that, when coexpressed, PSD-95, NR1, and D 1 coprecipitated with antibodies against either HA or NR1 (Fig. 1A) , suggesting that these proteins formed a multiprotein complex in these cells. NR1 or PSD-95 coprecipitated with the anti-HA antibody when each was coexpressed with HA-D 1 . Similarly, D 1 or PSD-95 coprecipitated with the anti-NR1 antibody when each was coexpressed with NMDA receptors. These data suggest that the tertiary complex is assembled by protein-protein interactions at multiple sites ( Fig. 1G ).
To establish whether or not the D 1 / PSD-95/NMDA receptor complex exists in vivo, we performed coimmunoprecipitation experiments on mouse forebrain lysates ( Fig. 1 B) . An anti-D 1 antibody precipitated a protein complex that included PSD-95 and several NMDA receptor subunits, NR1, NR2A, and NR2B. To confirm the immunoprecipitation data, we also examined the subcellular distributions of D 1 , PSD-95, and NR1 in cultured hippocampal neurons using immunofluorescence confocal microscopy. D 1 , PSD-95, and NR1colocalized in a substantial portion of dendritic spines/clusters along dendritic processes (Fig. 1C) . Together, these data provide support for the view that D 1 , PSD-95, and NMDA receptors coexist in the same protein complex in the brain.
PSD-95 and NR1 bind to an overlapping region on the D 1 carboxyl tail
Our previous studies demonstrate that PSD-95, via its NT, directly interacts with the CT of D 1 (D 1 CT) (Zhang et al., 2007) . A peptide fragment (L385-L415; D 1 CT2) in the middle of D 1 CT has been shown to interact with NR1 (Lee et al., 2002) . We investigated whether PSD-95 also binds this domain of D 1 CT using recombinant GST affinity purification assays ( Fig. 1 D-F ) . GST fusion proteins encoding the various fragments of D 1 CT were constructed and used as baits to precipitate associated proteins ( Fig. 1 E) . Incubation of GST, GST-D 1 CT1, GST-D 1 CT2, or GST-D 1 CT3 fusion proteins with lysates prepared from HEK293 cells expressing PSD-95 revealed a copurification of PSD-95 and GST-D 1 CT2 or GST-D 1 CT3, but not GST-D 1 CT1 or GST alone (Fig. 1F) . Similarly, GST-D 1 CT2 or GST-D 1 CT3, but not GST-D 1 CT1 or GST, was able to pull down PSD-95 from protein extracts prepared from mouse striatal cultures. These data suggest that although they bind to distinct sequences, PSD-95 and NR1 recognize an overlapping region on the D 1 CT.
PSD-95 interferes with D 1 -NR1 interaction
By associating with a region on the D 1 CT that also mediates D 1 -NR1 interaction, PSD-95 could interfere with the physical coupling between the two receptors. To test this hypothesis, HEK293T cells were transfected with cDNAs encoding D 1 and NMDA receptors in the presence or absence of PSD-95 cotransfection ( Fig. 2 A-C) . The strength of D 1 -NR1 association was measured by coimmunoprecipitation using an antibody against NR1. PSD-95 coexpression affected neither the total D 1 nor NR1 Fig. 2 A, B) . In the presence of PSD-95, however, the anti-NR1 antibody precipitated a significantly lower amount of D 1 receptors, whereas the amount of coprecipitated NR1 protein remained the same (Fig. 2 A, C) . This result suggests that the presence of PSD-95 inhibited D 1 -NR1 association.
expression (
To investigate whether the PSD-95 inhibition of D 1 -NR1 interaction is mediated by PSD-95 NT, we generated several PSD-95 truncation mutants (Fig. 2 D) and analyzed their effects on D 1 -NR1 coprecipitation in cotransfected HEK293T cells (Fig. 2 E, F ) . PSD-95 NT, a 72-amino acid peptide alone in the absence of the three PDZ, SH3, and GK domains, diminished the D 1 -NR1 association indistinguishable from that induced by the fulllength PSD-95. Unexpectedly, a PSD-95 mutant lacking the NT (PSD-95 ⌬NT) still inhibited, albeit with less effectiveness (Fig. 2 F) , the D 1 -NR1 association. However, a mutant lacking both NT and PDZ1 and -2 domains (PSD-95 ⌬NT, 1&2) completely abolished the inhibition (Fig. 2 E, F ) . These data suggest that the PSD-95 NT is sufficient but not necessary for inhibiting D 1 -NR1 interaction, and the first two PDZ domains that mediate PSD-95-NMDA NR2 receptor interaction also participate in the negative regulation of D 1 -NR1 interaction.
Removal of PSD-95 enhances D 1 -NR1 association
To confirm the inhibition of PSD-95 on D 1 -NR1 interaction in vivo, we performed coimmunoprecipitation and Western blots on forebrain protein extracts prepared from wild-type mice (PSD-95 WT) and their littermates that lacked PSD-95 (PSD-95 KO) (Fig. 3A-D) . The total D 1 and NR1 levels were unaltered in PSD-95 KO mice. An anti-D 1 antibody precipitated a similar amount of D 1 but a significantly higher amount of NR1 in PSD-95 KO mice, compared with the WT control. Thus, more NR1 was associated with a similar amount of D 1 receptors in the absence of PSD-95.
To directly "visualize" the role of PSD-95 in D 1 -NR1 association, we examined the effect of shRNA-mediated PSD-95 knockdown on the colocalization of D 1 and NMDA receptors in cultured hippocampal neurons (Fig. 3E-G) . A shRNA carrying point mutations was used as a control (sh-control). Neurons were transfected with shRNA for PSD-95 (sh-PSD-95) or sh-control. Western blot analysis showed that sh-PSD-95 selectively silenced the expression of PSD-95 compared with sh-control ( Fig. 3E) (Elias et al., 2006) . Neurons expressing shRNAs were identified by their expression of GFP (Fig. 3F) . D 1 receptor colocalization with NR1 in dendritic puncta/clusters was significantly higher in neurons expressing sh-PSD-95 than in neurons expressing sh-control (Fig. 3F,G) . This increase occurred without changes in the densities of D 1 or NR1 puncta (data not shown). Collectively, these results suggest that PSD-95 fine-tunes the D 1 -NMDA receptor association within the same complex.
PSD-95 removes NMDA receptor inhibition of D 1 internalization
The responsiveness of the D 1 receptor, like most G-proteincoupled receptors (GPCRs), is controlled primarily by the classical ␤-arrestin-and GPCR kinase (GRK)-regulated desensitization process . Association with NMDA receptors immobilizes D 1 receptors in the plasma membrane and abolishes agonist-induced D 1 desensitization (Fiorentini et al., 2003) . We thus investigated the functional significance of the PSD-95 interference of D 1 -NR1 association by determining the effect of PSD-95 on this D 1 trafficking process using an immunocytochemistry-based internalization assay (Zhang et al., 2007) . HEK293 cells were transfected with HA-D 1 and NMDA receptors in the presence or absence of PSD-95-GFP. Surface HA-D 1 receptors were labeled with an anti-HA antibody, and the internalization of these receptor-antibody complexes was monitored in live cells (Fig. 4) . Consistent with previous studies (Fiorentini et al., 2003; Zhang et al., 2007) , HA-D 1 , when expressed alone (Fig. 4 A) or coexpressed with NMDA receptors (Fig. 4C) , displayed little constitutive endocytosis but showed substantial spontaneous internalization when coexpressed with PSD-95 (Fig. 4 B) . Stimulation with SKF81297 (10 M, 30 min), a full D 1 agonist, induced robust internalization of the HA-D 1 receptors, regardless of the presence of NMDA receptor and/or PSD-95 overexpression (Fig. 4) .
We then examined how PSD-95 might regulate D 1 internalization as a consequence of NMDA receptor coactivation. In cells cotransfected with HA-D 1 and NMDA receptors, simultaneous stimulation of NMDA receptors with NMDA (50 M)/glycine (10 M) inhibited the SKF 81297-induced D 1 internalization (Fig. 4C, 5E ). This inhibition was blocked by the NMDA receptor antagonist (ϩ)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate (MK-801) (10 M), indicating the requirement for NMDA receptor activation (Fig. 4C ). In contrast, this NMDA receptor-dependent inhibition of D 1 internalization was abolished in cells cotransfected with D 1 , NMDA receptor, and PSD-95 (Fig. 4 D, 5E) . tors alters the rules that govern NMDA receptor modulation of D 1 endocytosis without affecting the level or distribution of these receptors.
Domain mapping of PSD-95 disinhibition of D 1 internalization
We next investigated the domain mechanism by which PSD-95 removes, or disinhibits, the NMDA receptor-mediated inhibition of D 1 internalization by analyzing the effect of PSD-95 truncation mutants on D 1 internalization in cotransfected HEK293 cells (Fig. 5) . Consistent with the involvement of both PSD-95 NT and PDZ1 and -2 domains in inhibiting D 1 -NR1 interaction, deletion of either domain, but not both, still mimicked full-length PSD-95 in disinhibiting the NMDA receptor-dependent inhibition of D 1 internalization. In particular, either PSD-95 ⌬NT (Fig. 5 B, E) or PSD-95 ⌬1&2 (Fig. 5C,E) blocked the NMDA receptor- . Surface receptors were live-conjugated with an anti-HA antibody, and were allowed to undergo endocytosis (37°C, 30 min) under the indicated stimulation conditions. After internalization, cells were processed for differential staining of remaining surface (Sur., before permeabilization) and internalized (Inter., after permeabilization) receptors.
dependent inhibition of D 1 internalization in a manner indistinguishable from that induced by the full-length PSD-95 (Fig. 5A,E) . In contrast, PSD-95 ⌬NT, 1&2 (Fig. 5D ) failed to block the NMDA receptor-mediated inhibition of D 1 internalization and instead induced D 1 internalization patterns similar to those of cells expressing HA-D 1 and NMDA receptors in the absence of PSD-95 coexpression (Fig. 5E ). These data suggest that both the NT and PDZ1 and -2 domains of PSD-95 are involved in disinhibiting the NMDA receptor-dependent inhibition of D 1 internalization.
PSD-95 knockdown enables inhibition of D 1 internalization by NMDA receptors
We further investigated the role of PSD-95 in the NMDA receptor-dependent modulation of D 1 trafficking in neurons us- ing a receptor internalization assay (Fig. 6 ). Cultured hippocampal neurons were cotransfected with HA-D 1 and sh-PSD-95 or sh-control, live labeled with an anti-HA antibody, stimulated, and processed for differential labeling and measurements of surface and internalized HA-D 1 receptors, respectively (Fig. 6 A, B) . In both control (expressing sh-control) and PSD-95 knockdown (expressing sh-PSD-95) neurons, SKF 81297 (10 M) alone induced robust HA-D 1 internalization, whereas NMDA (50 M)/ glycine (10 M) alone had no effect (Fig. 6C) . The SKF 81297-induced HA-D 1 internalization was abolished by the D 1 antagonist SCH23390 (10 M), suggesting that this process was specifically mediated by D 1 (data not shown). However, simultaneous stimulation of NMDA receptors during D 1 stimulation significantly inhibited the SKF81297-induced D 1 internalization in PSD-95 knockdown neurons, but had no significant effect in control neurons (Fig. 6C) . These data are consistent with the idea that under normal conditions, a physiological role for PSD-95 is to uncouple modulation of D 1 trafficking by NMDA receptors.
PSD-95 blocks NMDA receptor modulation of D 1 signaling
The strength of D 1 signaling is typically measured by the level of cAMP produced as a consequence of receptor activation. Because receptor trafficking is an integral regulatory mechanism of GPCR signaling, we hypothesized that PSD-95 may also uncouple D 1 cAMP signaling from NMDA receptor modulation. A stable HEK293 cell line constitutively expressing the rhesus macaque D 1 receptor (Zhang et al., 2007) was transiently transfected with NMDA receptors in the presence or absence of PSD-95 overexpression. D 1 signaling was assessed by dose-response curves of D 1 -mediated cAMP production in response to various concentrations of SKF 81297 stimulation (Fig. 7) . Consistent with a previous study (Pei et al., 2004) , activation of NMDA receptors overexpressed in D 1 -stable cells significantly enhanced the SKF 81297-stimulated, D 1 -mediated cAMP accumulation (Fig.  7 A, C) . NMDA receptor activation increased the maximal cAMP levels (B max ) induced by saturating doses of SKF 81297, but did not significantly alter the EC 50 of SKF 81297 (no stimulation: 4.4 Ϯ 2.4 ϫ 10 Ϫ8 M; stimulation: 6.4 Ϯ 3.2 ϫ 10 Ϫ8 M; p Ͼ 0.05). The potentiation was blocked by the NMDA receptor antagonist MK-801, confirming that NMDA receptor activation was required for this potentiation (Fig. 7A) . In contrast, NMDA receptor activation-dependent potentiation of D 1 function was absent (or slightly reversed) in D 1 -stable cells coexpressing both NMDA receptors and PSD-95 (Fig. 7 B, C) . These results suggest that PSD-95 association with the D 1 -NMDA heteroreceptor complex abolished the ability of NMDA receptor activation to potentiate D 1 cAMP signaling.
To determine whether the PSD-95 abolishment of NMDA receptor modulation of D 1 cAMP signaling requires activation of the NMDA receptor per se, we repeated the above experiments in the absence of NMDA receptor stimulation (Fig. 7D) . We found that, when transfected into the D 1 -stable cells, unstimulated NMDA receptors significantly suppressed the SKF 81297-induced, D 1 -mediated cAMP accumulation (Fig.  7D ). This finding is consistent with the current evidence that most physical heteroreceptor interactions lead to mutual inhibitory effects (Ginés et al., 2000; Liu et al., 2000; Hillion et al., 2002; Lee et al., 2002) . PSD-95 removed, at least partially, this NMDA receptor-mediated inhibition of D 1 signaling in D 1 -stable cells cotransfeccted with both NMDA receptor and PSD-95. These data indicate that activation of these receptors or their Ca 2ϩ -coupled downstream signaling is not necessary for the PSD-95 interference of D 1 -NMDA receptor interaction.
Finally, we investigated whether PSD-95 might modulate the agonist binding efficacy of the NMDA receptor-associated D 1 receptor. Radioligand competition binding experiments were performed to quantify the number as well as agonist binding parameters of D 1 in D 1 -stable cells transfected with NMDA receptors in the presence or absence of PSD-95 coexpression, using the ligand [ 3 H]SCH23390 and increasing concentrations of SKF 81297 (Fig. 7E ). PSD-95 overexpression had no effect on either the total number of D 1 receptors expressed or the IC 50 of SKF 81297 (Fig. 7F) , suggesting that the ligand-binding properties of the receptor were not modified by PSD-95. Together, the effects of PSD-95 on NMDA receptordependent modulation of D 1 signaling are independent of a modification of D 1 pharmacological profiles.
PSD-95 knockdown escalates NMDA receptor-dependent D 1 cAMP signaling in striatal neurons
The role of endogenous PSD-95 in NMDA receptor-dependent modulation of D 1 signaling was examined in cultured striatal neurons infected with lentivirus (Lois et al., 2002) expressing sh-PSD-95. To rule out potential viral-associated side effects, lentivirus expressing sh-control was used as a control. sh-PSD-95 eliminated the vast majority of endogenous PSD-95 in striatal neurons compared with sh-control (Fig. 8 A) . This represents an underestimate of the knockdown efficiency in infected cells, because our infection efficiency routinely reached 70%. In control neurons, stimulation of the D 1 -class receptors with SKF 81297 (10 M, 30 min) increased cAMP accumulation (Fig. 8 B) . Simultaneous activation of NMDA receptors by NMDA (50 M)/glycine (10 M) during D 1 stimulation did not further increase, and in fact inhibited, the SKF 81297-induced, D 1 -mediated cAMP production (Fig. 8 B, C) , an effect that was blocked by MK-801 (10 M) (Fig.  8 B) . This result suggests that an endogenous protective mechanism may exist under normal conditions. Acute PSD-95 knockdown in sh-PSD-95 expressing cultures retained SKF 81297-induced cAMP production activity (Fig. 8 B) . However, concomitant stimulation of NMDA receptors elicited a significant increase of SKF81297-induced cAMP levels (Fig. 8 B, C) , which was partially reversed by MK-801 (10 M) (Fig. 8 B) . These data support the hypothesis that a normal role for PSD-95 is to prevent excessive potentiation of D 1 signaling by NMDA receptors.
Discussion
In this study, we identified a novel gain of function for the prototypical synaptic scaffold PSD-95 and illustrated a mechanism by which the physical and functional interplay between DA and glutamate systems can be fine-tuned by this glutamatergic scaffold. We show that PSD-95, D 1 , and NMDA receptors are components of a multiprotein complex. Within the complex, PSD-95 inhibits the physical association between D 1 and NMDA receptors and functionally uncouples D 1 receptor trafficking and signaling from modulation by NMDA receptors. This PSD-95 interference may represent an effective means to weaken the constitutive D 1 -NMDA receptor interaction and to prevent this interaction from being abnormally strengthened by DA and/or glutamate during neural activity. Because concomitant overactivation of both D 1 and NMDA receptors can be detrimental to functional and structural integrity of neurons, our study illustrates a mechanism by which the D 1 -NMDA receptor coupling can be dampened to afford neuroprotection (Fig. 9) .
At least three distinct interactions may contribute to the assembly of the D 1 /PSD-95/NMDA receptor complex: the D 1 -NR1 interaction mediated by the CTs of these receptors, the D 1 -PSD-95 interaction mediated by the NT of PSD-95 and CT of D 1 , and the PDZ-mediated interactions between PSD-95 and NR2 subunits. Our data demonstrate that these protein-protein interactions are not always cooperative to stabilize a multiprotein complex, and, to the contrary, some may even be antagonizing to destabilize formation of the complex. In particular, by associating with both D 1 and NMDA receptors, PSD-95 interferes with the interaction between these receptors. Our deletion analyses suggest that the PSD-95 interference is mediated by both the NT and PDZ1 and -2 domains of PSD-95. Although PSD-95 NT may conceivably inhibit NR1 association with the D 1 receptor because the two proteins bind an overlapping region on the D 1 CT, the mechanism by which the PDZ1 and -2 domains also contribute to the disruption of D 1 -NMDA receptor complex formation is less clear.
Two mechanisms, perhaps acting in a synergistic manner, may mediate the PSD-95 interference of NMDA receptor modulation of D 1 signaling. First, the interference may be achieved through a direct, physical obstruction of D 1 -NR1 coupling by the presence of PSD-95, independent of intracellular signaling (Fig.  9C) . Previous work indicates that the enhancement of D 1 cAMP signaling by NMDA receptor activation depends on the physical interaction between the two receptors, because it is abolished by overexpression of mini genes encoding either D 1 or NR1 CT fragments that disrupt D 1 -NR1 interaction (Pei et al., 2004) . The ability of PSD-95 to mimic these peptide fragments in inhibiting D 1 -NR1 association and blocking the suppression of D 1 cAMP signaling by unstimulated NMDA receptors suggests that PSD-95 can serve as a simple physical barrier.
A second mechanism by which PSD-95 may interfere with NMDA receptor modulation of D 1 signaling is through downstream signaling complexes that may be recruited by PSD-95. These signaling modalities may respond to NMDA receptormediated Ca 2ϩ influx and participate in regulation of D 1 -mediated signaling (Fig. 9C) . Indeed, both our in vitro (Fig. 7) and in vivo (Fig. 8) NMDA receptor-mediated D 1 signaling enhancement can be explained, at least in part, by surface recruitment/retention of D 1 receptors after NMDA receptor stimulation. In both heterologous cells and cultured neurons, NMDA receptor activation recruits D 1 receptors to the plasma membrane Pei et al., 2004) , perhaps via a SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor)-dependent mechanism (Pei et al., 2004) . In cultured striatal slices, ligand-occupied NMDA receptors have been shown to recruit laterally diffusing D 1 receptors to dendritic spines through a diffusion-trap mechanism (Scott et al., 2006) . Here, we found that NMDA receptors also immobilize D 1 receptors on the cell surface. In all three cases, interestingly, stimulation of NMDA receptors is necessary for their action (but see Fiorentini et al., 2003) . In this context, it is of interest to note that stimulated and nonstimulated NMDA receptors exert opposite modulations on D 1 signaling in cells coexpressing D 1 and NMDA receptors. That is, stimulated NMDA receptors potentiate, whereas nonstimulated receptors inhibit D 1 -mediated cAMP signaling. The mechanism(s) underlying this inhibition is currently unknown, but could involve downregulation of total D 1 receptor expression, suppression of surface D 1 receptor level, alteration of D 1 pharmacological profiles, and/or clamp of D 1 at a less effective state (e.g., via conformational changes). Regardless of the mechanisms, it appears that ligand occupancy of NMDA receptors can release this "clamp" through, for example, an allosteric conformational change of the receptor that leads to increased D 1 -NMDA receptor association (Pei et al., 2004; Scott et al., 2006) , which can be further fine-tuned by PSD-95. This may represent a delicate switch by which glutamate can gate D 1 signaling through opening D 1 -associated NMDA receptors.
Activation of D 1 receptors is long recognized to enhance NMDA receptor-mediated responses in the cortex (Cepeda et al., 1992; Seamans et al., 2001; Gonzalez-Islas and Hablitz, 2003; Chen et al., 2004) and striatum (Cepeda et al., 1993; Blank et al., 1997; Snyder et al., 1998; Flores-Hernández et al., 2002) , involving primarily the cAMP/PKA/DARPP-32/PP1 cascade. Together with the reciprocal facilitation of D 1 receptor function as a consequence of NMDA receptor activation, a positive feedback would be created that, if left uncontrolled, could result in overactivation of both D 1 and NMDA receptors. Excessive activation of the NMDA receptor mediates excitotoxicity associated with neurodegenerative diseases and traumatic brain injuries (Choi, 1988; Lipton and Rosenberg, 1994) . Elevated DA tone is also neurotoxic, contributing to the degeneration of postsynaptic DA-receiving neurons, via receptor-independent mechanisms involving oxidative stress-induced apoptosis and largely undefined receptor-dependent mechanisms (Cyr et al., 2003; Bozzi and Borrelli, 2006) . Among all DA targets, the striatum is the most densely innervated and a particularly susceptible region for degeneration. We showed that NMDA receptor activation failed to enhance, and in fact suppressed, the D 1 agonist-induced cAMP signaling in normal striatal neurons but increased this response in PSD-95 knockdown striatal neurons. Interestingly, activation of NMDA receptors enhances D 1 function in hippocampal cultures (Pei et al., 2004) . These studies suggest that the positive coupling between D 1 and NMDA receptor is normally under control, at least in the striatum, and that the PSD-95 interference may represent such a negative control mechanism in this region.
The PSD-95-mediated interference reported here provides an efficient and novel means to constitutively dampen excessive D 1 -NMDA receptor stimulation. Another pharmacologically distinct family of receptors that mediates DA actions is the D 2 -class 
